Arcutis Biotherapeutics
ARQT
ARQT
235 hedge funds and large institutions have $2.37B invested in Arcutis Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 86 increasing their positions, 83 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
3% more funds holding
Funds holding: 229 → 235 (+6)
4% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 83
1.72% less ownership
Funds ownership: 106.61% → 104.89% (-1.7%)
Holders
235
Holding in Top 10
7
Calls
$10.9M
Puts
$2.77M
Top Buyers
| 1 | +$37.7M | |
| 2 | +$21.6M | |
| 3 | +$15.7M | |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$11.4M |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
+$6.33M |
Top Sellers
| 1 | -$20.8M | |
| 2 | -$19.9M | |
| 3 | -$14.3M | |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$11M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$10.6M |
